Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Collegium Pharmaceuticals has experienced significant changes in leadership and strategy, with Vikram Karnani recently appointed as CEO and an acquisition made towards the end of 2024 to diversify the company's revenue streams [1] Company Overview - The company is focusing on growth through strategic acquisitions, which is expected to enhance its product offerings and market position [1] - The leadership team includes the CEO, CFO Colleen Tupper, and Chief Commercial Officer Scott Dreyer, indicating a strong executive presence to guide the company's future [1] Performance and Guidance - Collegium Pharmaceuticals has raised its guidance multiple times throughout the year, suggesting better-than-expected performance in 2025 [1] - The company is positioned to discuss its performance metrics and strategic outlook in detail during the conference [1]